(E)-1,5-bis(4-hydroxy-3-methoxyphenyl)pent-4-ene-1,3-dione | 1001203-60-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-1,5-bis(4-hydroxy-3-methoxyphenyl)pent-4-ene-1,3-dione
• 英文别名: (E)-1,5-bis-(4-hydroxy-3-methoxyphenyl)-pent-4-ene-1,3-dione
• CAS: 1001203-60-6
• 化学式: C₁₉H₁₈O₆
• 分子量: 342.348
• InChiKey: WGRFGQJWSXSKER-ZZXKWVIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (E)-1,5-bis(4-hydroxy-3-methoxyphenyl)pent-4-ene-1,3-dione 在 一水合肼 、 溶剂黄146 作用下， 以83%的产率得到(E)-4-(2-(5-(4-hydroxy-3-methoxyphenyl)-1H-pyrazol-3-yl)vinyl)-2-methoxyphenol
  参考文献：
  名称：

  Synthesis and tubulin-binding properties of non-symmetrical click C5-curcuminoids

  摘要：

  A click-type entry into shortened curcuminoids of the diarylpentanoid type has been developed. The reaction is ideally suited to generate non-symmetrical analogues of curcumin, a class of natural products difficult to access but of growing biomedical relevance and special mechanistic interest to investigate the unique binding mode of curcumin to tubulin. Investigation of a series of click diarylpentane curcuminoids and their pyrazole adducts in various cellular tubulin functional assays validated this class of compounds as a novel type of anti-mitotic agents, evidencing structure-activity relationships, and identifying the pyrazole adduct 4k as a promising lead. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.053
• 作为产物：
  描述：

  1-(4-hydroxy-3-methoxyphenyl)butane-1,3-dione 、 香草醛 在 boron trioxide 、 硼酸三甲酯 、 正丁胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以56%的产率得到(E)-1,5-bis(4-hydroxy-3-methoxyphenyl)pent-4-ene-1,3-dione
  参考文献：
  名称：

  Synthesis and tubulin-binding properties of non-symmetrical click C5-curcuminoids

  摘要：

  A click-type entry into shortened curcuminoids of the diarylpentanoid type has been developed. The reaction is ideally suited to generate non-symmetrical analogues of curcumin, a class of natural products difficult to access but of growing biomedical relevance and special mechanistic interest to investigate the unique binding mode of curcumin to tubulin. Investigation of a series of click diarylpentane curcuminoids and their pyrazole adducts in various cellular tubulin functional assays validated this class of compounds as a novel type of anti-mitotic agents, evidencing structure-activity relationships, and identifying the pyrazole adduct 4k as a promising lead. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.053

文献信息

• Chemical Compounds
  申请人：Rees David Daryl

  公开号：US20080045591A1

  公开（公告）日：2008-02-21

  Compounds of general formula I: wherein: R 1 and R 2 are, independently of each other, selected from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted —CO—(C 1-10 alkyl), optionally substituted C 3-10 cycloalkyl, optionally substituted —CO—(C 3-10 cycloalkyl), optionally substituted C 2-10 alkenyl, optionally substituted —CO—(C 2-10 alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R 1 and R 2 together represent an optionally substituted saturated or unsaturated C 1-10 alkylidene group, or an optionally substituted saturated or unsaturated C 3-10 cycloalkylidene group, or R 1 and R 2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R 3 , which may be the same as, or different from, either of R 1 and R 2 , is selected from optionally substituted C 1-10 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted C 2-10 alkenyl, and optionally substituted aryl; R 4 , R 5 and R 6 are, independently of each other, selected from hydrogen, optionally substituted C 1-10 alkyl, OH, optionally substituted C 1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C 1-10 alkyl)-S(O) n — where n=0, 1 or 2, optionally substituted aryl-S(O) n — where n=0, 1 or 2, or R 4 is hydrogen and R 5 and R 6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R 1 ═R 2 =hydrogen, then any optionally substituted C 1-10 alkyl or optionally substituted C 2-10 alkenyl for R 3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R 3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.

  通式I的化合物： 其中： R1和R2独立地选自氢，可选取代的C1-10烷基，可选取代的—CO—（C1-10烷基），可选取代的C3-10环烷基，可选取代的—CO—（C3-10环烷基），可选取代的C2-10烯基，可选取代的—CO—（C2-10烯基），可选取代的芳基和可选取代的—CO-芳基，或者R1和R2一起代表一个可选取代的饱和或不饱和的C1-10烷基亚基，或一个可选取代的饱和或不饱和的C3-10环烷基亚基，或者R1和R2与它们连接的碳原子一起代表一个可选取代的含有3、4、5、6、7或8个环碳原子和可选取代的1、2或3个从O、N和S中选取的环杂原子的饱和或不饱和的有机环； R3可以与R1和R2中的任何一个相同或不同，选自可选取代的C1-10烷基，可选取代的C3-10环烷基，可选取代的C2-10烯基和可选取代的芳基； R4、R5和R6独立地选自氢，可选取代的C1-10烷基，OH，可选取代的C1-10烷氧基，卤素，可选取代的芳氧基，可选取代的（C1-10烷基）-S（O）n-，其中n=0、1或2，可选取代的芳基-S（O）n-，其中n=0、1或2，或者R4为氢，R5和R6一起代表一个可选取代的含有1、2、3、4、5、6或7个链碳原子和可选取代的1、2或3个链杂原子的饱和或不饱和的有机链，前提是该链至少由3个原子组成； 但是，当R1=R2=氢时，R3必须选取一个可选取代的C1-10烷基或可选取代的C2-10烯基，其中至少有一个分支点位于从R3所连接的羰基（或其互变异构体）计算的α和β位置之一；或其生理上可接受的盐、络合物或前药，本发明公开了其本身和用于治疗或预防过敏、平滑肌障碍、痉挛性疾病、过敏性疾病、炎症性疾病和/或疼痛。
• Chemical compounds
  申请人：Phytopharm PLC

  公开号：US07589123B2

  公开（公告）日：2009-09-15

  Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycloalkyl, optionally substituted C2-10alkenyl, and optionally substituted aryl; R4, R5 and R6 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, OH, optionally substituted C1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C1-10alkyl)-S(O)n— where n=0, 1 or 2, optionally substituted aryl-S(O)n— where n=0, 1 or 2, or R4 is hydrogen and R5 and R6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R1═R2=hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.

  通式I的化合物，其中：R1和R2是独立选择的氢、可选择取代的C1-10烷基、可选择取代的—CO—（C1-10烷基）、可选择取代的C3-10环烷基、可选择取代的—CO—（C3-10环烷基）、可选择取代的C2-10烯基、可选择取代的—CO—（C2-10烯基）、可选择取代的芳基和可选择取代的—CO-芳基，或者R1和R2共同表示可选择取代的饱和或不饱和的C1-10烷基亚基，或可选择取代的饱和或不饱和的C3-10环烷基亚基，或者R1和R2与它们所附着的碳原子共同表示可选择取代的含3、4、5、6、7或8个环碳原子和可选择从O、N和S中选取1、2或3个环杂原子的有机环；R3可能与R1和R2中的任何一个相同或不同，选择可选择取代的C1-10烷基、可选择取代的C3-10环烷基、可选择取代的C2-10烯基和可选择取代的芳基；R4、R5和R6独立选择的是氢、可选择取代的C1-10烷基、OH、可选择取代的C1-10烷氧基、卤素、可选择取代的芳氧基、可选择取代的（C1-10烷基）-S（O）n-其中n = 0,1或2，可选择取代的芳基-S（O）n-其中n = 0,1或2，或者R4是氢，R5和R6共同表示可选择取代的含1、2、3、4、5、6或7个链碳原子和可选择从O、N和S中选取1、2或3个链杂原子的有机链，前提是链至少有3个原子长；但是，当R1═R2=氢时，R3的可选择取代的C1-10烷基或可选择取代的C2-10烯基必须在从R3所附着的羰基（或其互变异构体）计数的α和β位置中的一个或多个位置具有分支点；或其生理上可接受的盐、复合物或前药。本发明公开了该化合物本身及其在治疗或预防过敏、平滑肌障碍、痉挛性疾病、过敏症、炎症病症和/或疼痛方面的用途。
• WO2008/3978
  申请人：——

  公开号：——

  公开（公告）日：——
• DIOXO-ALKANES AND DIOXO-ALKENES
  申请人：PHYTOPHARM PLC

  公开号：EP2046311A2

  公开（公告）日：2009-04-15
• US7589123B2
  申请人：——

  公开号：US7589123B2

  公开（公告）日：2009-09-15